The global dietary supplements market continues to expand at a steady pace. Recent estimates place the sector at roughly $210 billion today, with projections approaching $400 billion by 2033, implying sustained high-single-digit annual growth driven by aging populations, rising health awareness, and a consumer shift toward preventative wellness. Within that, demand for science-backed, bioavailable formulations is accelerating. The companies building around specific, clinically relevant biological mechanisms are beginning to separate from the noise.
Below are four names across this space, each with a distinct angle, a different stage of development, and a story worth understanding.
Cellev8 Nutrition Inc. (OTCID: CELV)
Cellev8 Nutrition isn’t competing on a broad multivitamin strategy. The Wellington, Florida-based company has built its entire platform around superoxide dismutase, or SOD, one of the body’s most critical endogenous antioxidants, responsible for neutralizing the free radicals generated through normal metabolic activity. The delivery challenge around SOD has historically been significant. Cellev8’s proprietary VitaShield™ system is designed to solve it, delivering what the company says is over twice the efficacy of conventional antioxidant products through improved stability and cellular absorption.
What makes the story increasingly credible is who’s now behind it. In January, Cellev8 appointed Dr. Guangshuo “Alan” Zhu, MD, to its Board of Directors. Dr. Zhu is a former lab director at Johns Hopkins University’s Cardiovascular Physiology and Hemodynamic Core Laboratory with more than 50 peer-reviewed publications in journals including Nature and Circulation. His career has centered specifically on oxidative stress and SOD-mediated pathways. The scientific alignment is about as direct as it gets.
Equally notable is where the products are already showing up: more than 60 professional sports teams across the NFL, NBA, MLB, NHL, MLS, and Olympic programs. Six product SKUs, delivered as gummies rather than pills or powders, round out a portfolio designed for daily use across demographics from 8 to 80.
CELV is early-stage and OTC-listed, but the scientific foundation, elite-level traction, and consumer-friendly format make it a name to watch closely.
Niagen Bioscience (NASDAQ: NAGE)
If Cellev8 represents what a single-molecule supplement platform can become, Niagen Bioscience offers a compelling picture of where it can go. Formerly ChromaDex Corp., NAGE has spent years building the definitive NAD+ platform around its patented ingredient Niagen, specifically nicotinamide riboside (NR), the most clinically studied NAD+ precursor available. The parallel to CELV’s SOD platform is straightforward: both companies identified a specific, scientifically significant biological mechanism, built proprietary delivery around it, and commercialized it into a consumer supplement.
The financial momentum at NAGE is hard to ignore. The company recently reported full-year 2025 net sales of $129.4 million, a 30% increase year-over-year, with net income more than doubling to $17.4 million. Adjusted EBITDA grew 139% to $20.4 million. The company is guiding for 10 to 15% additional top-line growth in 2026, and its balance sheet is clean with $64.8 million in cash at year-end.
March has been an active month. NAGE is the premiere sponsor of the inaugural NAD for Health: Opportunities and Challenges scientific conference hosted by the University of Copenhagen, taking place March 23 through 25 at the Royal Danish Academy of Sciences and Letters. The event brings together the world’s foremost NAD researchers to advance clinical translation, underscoring NAGE’s positioning at the center of the broader longevity science conversation. The company also recently divested its non-core ChromaDex Reference Standards business to sharpen focus on NAD+ IP and commercial growth, expanded HSA/FSA purchasing access for Tru Niagen consumers, and launched Tru Niagen Beauty, its first NAD+ skincare supplement. A newly granted U.S. patent covers NR use in intravenous and injectable formulations, extending protection through 2044. NAGE is the blueprint.
Mannatech, Incorporated (NASDAQ: MTEX)
Where NAGE and CELV are built around single-molecule platforms, Mannatech takes a broader formulation approach centered on its proprietary glyconutrient technology, most prominently Ambrotose, a complex carbohydrate supplement supported by its own body of published research. The Flower Mound, Texas-based company has been operating in the nutritional supplement space since 1993 and has built one of the more durable global direct-selling distribution networks in the category, active across more than 25 countries spanning the Americas, Europe, Asia-Pacific, and Africa.
The financial picture at MTEX reflects a company that knows how to find its footing. After a tough stretch driven by macroeconomic pressure in Asia-Pacific and unfavorable foreign exchange, the most recent annual results showed a meaningful operational reset: net income of $2.5 million for full-year 2024, swinging back from a net loss of $2.2 million the year prior. Q4 2024 gross margin expanded to 80.5%, up from 75.4% in the same period the year before, reflecting disciplined cost management and supply chain improvements. The company achieved that margin expansion even as revenue declined, which speaks to the underlying unit economics of the business.
The reappointment of Robert A. Toth as vice chairman signals a renewed focus on international expansion. Toth previously oversaw Avon International operations across 120-plus countries, and his return to an active leadership role suggests management is serious about leveraging the company’s global infrastructure more aggressively. For investors, MTEX represents a different kind of wellness bet: less about cutting-edge science and more about the commercial machinery required to move product at scale. At current valuation levels, the market is pricing in considerable skepticism, which may itself be part of the opportunity.
Codexis, Inc. (NASDAQ: CDXS)
Codexis doesn’t sell a supplement. What it sells is something arguably more foundational: the ability to engineer enzymes that make previously impossible biological processes scalable and commercially viable. That capability, built on its proprietary CodeEvolver platform, is what makes CDXS the most intellectually interesting name in this group and also the most speculative.
The strategic pivot at Codexis is well underway. The company has refocused almost entirely on its ECO Synthesis platform, a proprietary enzyme-catalyzed manufacturing process for RNA interference therapeutics, one of the fastest-growing modalities in pharmaceutical development. A $37.8 million Technology Transfer Agreement with Merck, completed in Q4 2025, validated both the platform and the commercial appetite around it. Full-year 2025 revenue came in at $70.4 million, up 19% from the prior year, and the company closed the year with $78.2 million in cash, providing runway through 2027. Revenue guidance for 2026 sits at $72 to $76 million, ahead of prior consensus estimates.
The enzymatic angle connects to the broader wellness and bioavailability conversation more directly than it might first appear. The same engineering capability Codexis applies to pharmaceutical RNA manufacturing is the kind of platform-level science that increasingly drives ingredient delivery innovation across health categories. The company achieved ISO 9001:2015 certification in early 2026 and is on track to begin GMP facility construction in the second half of the year, with full production capability targeted by end of 2027. CDXS is not a supplement company, but it may be building infrastructure that underpins the next generation of them.
Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ITMM Consulting LLC to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/